Corvus Pharmaceuticals, Inc.

Corvus trades with a jaw-dropping 25.56% short float, suggesting considerable bearish conviction despite the stock sitting 39.6% RSI—solidly neutral territory without oversold pressure. The biotech lacks earnings (n/a P/E), making it a pure R&D narrative bet, yet the $1.1B market cap indicates modest scale in the sector. That elevated short percentage combined with intermediate RSI presents a potential squeeze risk if clinical or commercial catalysts reignite momentum, though fundamental profitability remains absent. The stock sits below its 52-week highs, consistent with a risk-on biotech pullback.